Cargando…

COVID-19 vaccine induced autoimmune hepatitis-a first case series from India

Detalles Bibliográficos
Autores principales:	Iyengar, Sowmya, Kulkarni, Anand, Katukuri, Goutham Reddy, Sharma, Mithun, Reddy, Nageshwar, Padaki, Nagaraja Rao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	POSTER PRESENTATIONS: Thursday 23 June: Immune-mediated and cholestatic disease: Clinical aspects
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252383/ http://dx.doi.org/10.1016/S0168-8278(22)01023-6

Ejemplares similares

Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine
por: Kulkarni, Anand, et al.
Publicado: (2022)

Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER)
por: Codoni, Greta, et al.
Publicado: (2022)

Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis
por: Barreira, Ana, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

Post-COVID-19 cholangiopathy: does SARS-CoV-2 play a relevant role in histopathological findings?
por: de Almeida e Borges, Valéria Ferreira, et al.
Publicado: (2022)

Cholangiopathy after severe COVID-19: what do we know so far?
por: de Almeida e Borges, Valéria Ferreira, et al.
Publicado: (2022)

Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study
por: Hunyady, Peter, et al.
Publicado: (2022)

Extrahepatic autoimmune diseases in autoimmune hepatitis: Effect on mortality
por: Birn‐Rydder, Rasmine, et al.
Publicado: (2022)

Environmental risk factors are associated with autoimmune hepatitis
por: Lammert, Craig, et al.
Publicado: (2021)

COVID-19 Masquerading as Autoimmune Hepatitis (AIH) Flare—The First Report()
por: Kulkarni, Anand V., et al.
Publicado: (2022)

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation
por: Pape, Simon, et al.
Publicado: (2020)

Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE‐LIVER online survey
por: Wunsch, Ewa, et al.
Publicado: (2022)

Healthcare utilization and outcomes of living donor liver transplantation for patients with APASL-defined acute-on-chronic liver failure
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases
por: Li, Hu, et al.
Publicado: (2022)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses
por: Canha, Maria Ines, et al.
Publicado: (2022)

Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease
por: Samer, Al-Dury, et al.
Publicado: (2022)

Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines-a multicenter european study
por: Simão, André L., et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Outcomes of Liver Transplant Recipients Infected with COVID-19 is Similar to Non- liver Transplant Patients
por: Kulkarni, Dr Anand V., et al.
Publicado: (2022)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
por: Stadlbauer, Vanessa, et al.
Publicado: (2020)

The Simple Cholestatic Complaints Score is a valid and quick patient‐reported outcome measure in primary sclerosing cholangitis
por: van Munster, Kim N., et al.
Publicado: (2020)

Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation
por: Lytvyak, Ellina, et al.
Publicado: (2021)

A novel serum metabolomic panel distinguishes IgG4‐related sclerosing cholangitis from primary sclerosing cholangitis
por: Radford‐Smith, Daniel E., et al.
Publicado: (2022)

Symptom patterns in the daily life of PSC patients
por: van Munster, Kim N., et al.
Publicado: (2022)

Predictors of serious adverse events and non‐response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid
por: De Vincentis, Antonio, et al.
Publicado: (2022)

High prevalence of lower limb atherosclerosis is linked with the gut–liver axis in patients with primary biliary cholangitis
por: Ponziani, Francesca Romana, et al.
Publicado: (2022)

Impact on follow‐up strategies in patients with primary sclerosing cholangitis
por: Bergquist, Annika, et al.
Publicado: (2022)

Portal pressure is of significant prognostic value in primary biliary cholangitis
por: Warnes, Thomas W., et al.
Publicado: (2022)

Utility of fluorescence imitating brightfield imaging microscopy for the diagnosis of feline chronic enteropathy
por: Au Yeung, Sarah, et al.
Publicado: (2022)

COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation
por: Nedumannil, Leya, et al.
Publicado: (2022)

Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: a retrospective cohort study
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic
por: Ayonrinde, Oyekoya, et al.
Publicado: (2022)

Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program
por: Sypsa, Vana, et al.
Publicado: (2022)

Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia
por: Gulbiani, Lasha, et al.
Publicado: (2022)

mRNA COVID-19 vaccine effectiveness in liver transplant patients
por: Khan, Muhammad, et al.
Publicado: (2022)

Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan
por: Ashraf Hussain, Md Razeen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_51h7aqslqa3h31sqc8k05gig9b